- Home
- PTLO vs ETNB Comparison
PTLO vs ETNB Comparison
Compare PTLO & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTLO
- ETNB
- Stock Information
- Founded
- PTLO 1963
- ETNB 2018
- Country
- PTLO United States
- ETNB United States
- Employees
- PTLO N/A
- ETNB N/A
- Industry
- PTLO Restaurants
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- PTLO Consumer Discretionary
- ETNB Health Care
- Exchange
- PTLO Nasdaq
- ETNB Nasdaq
- Market Cap
- PTLO 821.9M
- ETNB 867.4M
- IPO Year
- PTLO 2021
- ETNB 2019
- Fundamental
- Price
- PTLO $9.23
- ETNB $8.04
- Analyst Decision
- PTLO Buy
- ETNB Buy
- Analyst Count
- PTLO 7
- ETNB 7
- Target Price
- PTLO $14.00
- ETNB $30.33
- AVG Volume (30 Days)
- PTLO 1.3M
- ETNB 800.5K
- Earning Date
- PTLO 11-05-2024
- ETNB 11-07-2024
- Dividend Yield
- PTLO N/A
- ETNB N/A
- EPS Growth
- PTLO 56.82
- ETNB N/A
- EPS
- PTLO 0.42
- ETNB N/A
- Revenue
- PTLO $713,803,000.00
- ETNB N/A
- Revenue This Year
- PTLO $6.53
- ETNB N/A
- Revenue Next Year
- PTLO $11.42
- ETNB N/A
- P/E Ratio
- PTLO $21.58
- ETNB N/A
- Revenue Growth
- PTLO 11.02
- ETNB N/A
- 52 Week Low
- PTLO $8.66
- ETNB $7.00
- 52 Week High
- PTLO $16.85
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- PTLO 19.76
- ETNB 44.02
- Support Level
- PTLO $8.78
- ETNB $7.44
- Resistance Level
- PTLO $10.69
- ETNB $8.09
- Average True Range (ATR)
- PTLO 0.43
- ETNB 0.44
- MACD
- PTLO -0.14
- ETNB -0.06
- Stochastic Oscillator
- PTLO 2.78
- ETNB 22.47
About PTLO Portillo's Inc.
Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. It owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, Barnelli's pasta, sides and soup, and desserts and shakes.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).